【摘要】 目的研究帕利哌酮缓释片对首发精神分裂症患者血脂代谢的影响。方法对43例首发精神分裂症患者在使用帕利哌酮治疗前以及治疗4、8、12周后应用PANSS量表测定,并测量患者身高、体重、腰围、血脂、空腹血糖、OGTT后2小时血糖、血压。结果①治疗4周后,PANSS总分及各项因子分较治疗前均降低,差异有统计学意义(P<0.01)。②治疗8周和12周后患者的体重指数和腰围与治疗前比较有明显变化,差异有统计学意义(P<0.05);而血脂、空腹血糖、OGTT后2小时血糖、血压等指标在治疗前后无明显变化,差异无统计学意义(P>0.05)。结论①帕利哌酮缓释片不仅能明显改善首发精神分裂症患者的阳性症状,而且也改善患者阴性症状。②帕利哌酮缓释片对首发精神分裂症患者体重有一定影响,而对其它代谢指标无明显影响。更多还原

【Abstract】 Objective To study the influence of paliperidone extended-release tablets on blood lipid metabolism of first-episode schizophrenia patients.Methods 43patients with schizophrenia were treated with paliperidone extended-release tablets.PANSS scale measurement,height,weight,waist circumference,blood lipid,fasting blood sugar,2hafter OGTT blood glucose and blood pressure were observed before and 4weeks,8weeks,12weeks after treatment.Results PANSS score and various factors points 4weeks after treatment were lower than that before(P<0.01).The body mass index and waist circumference eight weeks and 12weeks after treatment were more obvious changes(P<0.05).The blood lipid,fasting blood glucose,blood sugar 2hafter OGTT,blood pressure had no change before and after treatment(P>0.05).Conclusion Paliperidone extended-release tablets can significantly improve starting schizophrenia positive symptoms and the negative symptoms.Paliperidone extended-release tablets for first-episode schizophrenia patients have certain influence to weight,and other metabolic indices have no obvious influence.更多还原